Fig. 3From: The neutrophil-lymphocyte ratio has a role in predicting the effectiveness of nivolumab in Japanese patients with metastatic renal cell carcinoma: a multi-institutional retrospective studyKaplan-Meier curves for progression-free survival (PFS) of mRCC patients treated with nivolumab stratified by the neutrophil-lymphocyte ratio (NLR) at baseline (a), and the NLR at 4 weeks (b). Overall survival (OS) stratified by the NLR at baseline (c) and that at 4 weeks (d)Back to article page